The DELIVER trial confirmed the extended benefits of SGLT-2 inhibitors in terms of reduced heart failure hospitalization and cardiovascular death in patients with HFmrEF and HFpEF, regardless of the presence of type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.